Structure–Relaxivity Relationships of Magnetic Nanoparticles for Magnetic Resonance Imaging

Abstract

Magnetic nanoparticles (MNPs) have been extensively explored as magnetic resonance imaging (MRI) contrast agents. With the increasing complexity in the structure of modern MNPs, the classical Solomon-Bloembergen-Morgan and the outer-sphere quantum mechanical theories established on simplistic models have encountered limitations for defining the emergent phenomena of relaxation enhancement in MRI. We reviewed recent progress in probing MRI relaxivity of MNPs based on structural features at the molecular and atomic scales, namely the structure-relaxivity relationships, including size, shape, crystal structure, surface modification, and assembled structure. We placed a special emphasis on bridging the gaps between classical simplistic models and modern MNPs with elegant structural complexity. In the pursuit of novel MRI contrast agents, we hope this review will spur the critical thinking for design and engineering of novel MNPs for MRI applications across a broad spectrum of research fields.

IL-6-targeted ultrasmall superparamagnetic iron oxide nanoparticles for optimized MRI detection of atherosclerotic vulnerable plaques in rabbits

“…The relaxation signals of proton spin in the human body which excited by radiofrequency waves under a strong magnetic eld is the key factor in MRI work, 41,42 and the iron oxide magnetic nanoparticles could reduce the transverse relaxation time T 2 effectively and then generate negative enhancement effects on T 2 -related images. [43][44][45][46] The in vitro MRI result displays that Anti-IL-6-USPIO exhibit darker images with the increasing concentration of Fe, which indicates that the correlation between T 2 contrast enhancement effect and Fe (Fig. 1D).…”

Recent Advances of Bioresponsive Nano-Sized Contrast Agents for Ultra-High-Field Magnetic Resonance Imaging

“…techniques (Zhou et al, 2019). Cutting-edge interdisciplinary subjects of chemistry, physical, biological, and engineering shall also be included to resolve the current limitations of developing nanoparticle contrast agents.…”

“…When employing contrast agents for MRI, contrast agent shall possess the following distinct features for better imaging (Zhou et al, 2019): (a) Nano-size, achieve the maximum recognition; (b) diagnosis with high accuracy; (c) Compatibility, non-cytotoxic and biocompatible; (d) Stability, both chemical and photochemical stable; (e) Metabolism; renal excretion from body (Qin et al, 2007;Huang et al, 2010;Botar et al, 2020).…”

Iron oxide nanoparticles as multimodal imaging tools

“…However, these theories are simplied. They don't take into account the whole stet of parameters that can inuence the values of T 1 and T 2 relaxivities, which include: 26,27 Size of IONP, with small IONP acting as a positive contrast agent, e.g. r 1 increases from 3-30 mM À1 s À1 for IONP of $20-65 nm to 66 mM À1 s À1 for IONP of $5 nm, 28 and large IONP behaving as negative contrast agents, e.g.…”